Early safety and visual performance signals were reported at 3 months from a first-in-human (FIH) clinical study evaluating ...
Please provide your email address to receive an email when new articles are posted on . In the U.S. market, we currently have three newer multifocal IOLs approved for use: the Alcon Clareon PanOptix ...
Please provide your email address to receive an email when new articles are posted on . Part one of this series focused on balancing the three interrelated concepts of presbyopia-correcting or visual ...
“As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D—even with our leading products like PanOptix,” said Rob ...
The FineVision trifocal diffractive IOL has three focal points for far, near and intermediate vision. This study examines the outcome of bilateral implantation of this IOL and provides far, ...
Each year, more than 30 million people globally receive surgery to correct cataracts. As many people age, the crystalline lenses in their eyes become cloudy and obstruct their vision, but a simple and ...
VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results